| 18th week of 2011 patent applcation highlights part 46 |
| Patent application number | Title | Published |
|---|
| 20110104177 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE - The invention relates to histone deacetylase (HDAC) inhibitors to treat proliferative diseases. The present invention provides novel class III histone deacetylase inhibitors, in particular SIRT1 inhibitors, to reverse the silencing of hypermethylated genes, in combination with one or more other agents, in proliferative diseases such as cancer. The present invention provides methods of activating genes that are silenced by methylation in a subject by administering a HDAC inhibitor in combination with one or more agents. | 2011-05-05 |
| 20110104178 | NOVEL AVIAN ASTROVIRUS - The present invention relates to the fields of veterinary virology and immunology. In particular the invention relates to a novel avian Astrovirus; to antibodies or fragments thereof against the novel virus; to antigenic preparations, proteins, and DNA molecules of the novel avian Astrovirus; to vaccines of the novel virus or its antigenic preparations, protein, or DNA; to methods for the manufacture of such vaccines, and to diagnostic kits. | 2011-05-05 |
| 20110104179 | PROTEASE INHIBITORY PEPTIDES - The present invention relates to compounds, peptides, peptidomimetics and pharmaceutical compositions that inhibit protease activity, and the use of these compounds, peptides, peptidomimetics and pharmaceutical compositions comprising them to treat or prevent a condition. In particular the condition may be periodontal disease. The compounds, peptides and peptidomimetics may be obtained from various caseins, for example α-casein, β-casein and κ-casein. The protease activity which the compounds, peptides, peptidomimetics and pharmaceutical compositions of the invention inhibit includes that of the gingipains. | 2011-05-05 |
| 20110104180 | NEW VACCINE FOR THE TREATMENT OF MYCOBACTERIUM RELATED DISORDERS - The invention relates to genes and proteins involved in the sporulation of Mycobacteria and the use thereof in the technical fields of immunology and medicine. A vaccine comprising spore forming peptides, such as CotA or CotD, or antibodies thereto is used for the treatment of diseases caused by | 2011-05-05 |
| 20110104181 | MODULATION OF SYNAPTOGENESIS - The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or an α2δ subunit of a calcium channel. | 2011-05-05 |
| 20110104182 | CD40 ANTIBODY FORMULATION AND METHODS - The present invention provides a method of treating tumor in a patient comprising administering to said patient a CD40 agonist antibody according to an intermittent dosing schedule. The present invention also provides a method of treating tumor in a patient comprising administering a combination of a CD40 agonist antibody and a DNA replication inhibitor. Also provided is a formulation for use in the treatment. | 2011-05-05 |
| 20110104183 | USE OF SIP1 AS DETERMINANT OF BREAST CANCER STEMNESS - The present invention relates to the diagnosis and treatment of cancer. More specifically, it relates to the use of SIP1 nucleic acid and/or protein for the detection of breast cancer stem cells, and the repression of the gene and/or the inactivation of the protein to repress the differentiation of cells into cancer cells and to inhibit metastasis of breast cancer tumors. | 2011-05-05 |
| 20110104184 | ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS OF USE THEREOF - Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF. | 2011-05-05 |
| 20110104185 | ANTIBODY FRAGMENT-POLYMER CONJUGATES AND USES OF SAME - Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α | 2011-05-05 |
| 20110104186 | Small molecule immunopotentiators and assays for their detection - The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions. | 2011-05-05 |
| 20110104187 | METHOD OF TREATING GLYGOGEN STORAGE DISEASE - The present invention relates, in general, to Glycogen Storage Disease and, in particular, to a method of treating Glycogen Storage Disease-type-III and to compounds and compositions suitable for use in such a method. | 2011-05-05 |
| 20110104188 | NOVEL GLYCOLIPID AND USE THEREOF - The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof | 2011-05-05 |
| 20110104189 | COMPOSITIONS OBTAINED FROM CHLORELLA EXTRACT HAVING IMMUNOMODULATING PROPERTIES - The disclosed subject matter, in one aspect, relates to compounds and compositions {e.g., polysaccharides and polysaccharide complexes) and methods for providing and using such compounds and compositions. Disclosed are compositions comprising a polysaccharide or polysaccharide complex obtained from | 2011-05-05 |
| 20110104190 | MODIFIED BETA-LACTOGLOBULINS FOR IMMUNOTHERAPY OF MILK ALLERGY - The present invention is related to field of allergic (hypersensitivity) diseases and provides a method for producing modified allergenic polypeptides for use in immunotherapies. In the method of the invention, said allergenic polypeptides are modified so that they are not capable to form transient dimers. The invention also provides modified β-lactoglobulins for use in immunotherapy of milk allergy. | 2011-05-05 |
| 20110104191 | MALVA MOSAIC VIRUS AND VIRUS-LIKE PARTICLES AND USES THEREOF - The immunogenic properties of the potexvirus MaI va mosaic virus (MaMV) and virus-like particles (VLPs) comprising the coat proteins of MaMV are disclosed VLPs prepared from MaMV coat proteins, methods of preparing the VLPs, MaMV coat protein polypeptides and polynucleotides encoding the coat protein are taught. Further, immunogenic compositions comprising MaMV or a VLP comprising the MaMV coat protein alone or in combination with one or more antigens and the use of said compositions to vaccinate and/or induce an immune response in an animal are also taught. | 2011-05-05 |
| 20110104192 | NOROVIRUS AND SAPOVIRUS ANTIGENS - Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus. | 2011-05-05 |
| 20110104193 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 2011-05-05 |
| 20110104194 | IMMUNODOMINANT MYCOBACTERIUM TUBERCULOSIS PEPTIDES FROM CELL WALL PROTEINS FOR EARLY DIAGNOSIS AND IMMUNIZATION - A number of peptide epitopes and fragments from three | 2011-05-05 |
| 20110104195 | Plasmodium falciparum sporozoite and liver stage antigens - The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation. | 2011-05-05 |
| 20110104196 | IMMUNOGENIC COMPOSITION AND METHOD OF DEVELOPING A VACCINE BASED ON FUSION PROTEIN - The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants. | 2011-05-05 |
| 20110104197 | METHOD AND A FILTER FOR CAPTURING AIRBORNE AGENTS - A method for capturing airborne agents or products of agents, such as microorganisms, including viruses, and microbial antigens, toxins and allergens, comprising the formation of at least one curtain of charged particles in the form of an emulsion, a suspension or an aerosol, constantly renewing and regenerating said at least one curtain, and passing air containing airborne agents through said at least one curtain, which acting as a filter captures said agents; as well as a particle formulation for performing the method, comprising any charged particles dispersed in a liquid, including lipid-containing particles, e.g. in the form of an emulsion, or micelles, or lipid-containing particles in the form of an aerosol, or any other charged airborne particles in an aerosol. | 2011-05-05 |
| 20110104198 | CONSENSUS SEQUENCES OF CHIKUNGUNYA VIRAL PROTEINS, NUCLEIC ACID MOLECULES ENCODING THE SAME, AND COMPOSITIONS AND METHODS FOR USING THE SAME - Consensus CHIKV E1 protein, consensus CHIKV E2 protein, consensus CHIKV capsid protein, or fragments and homologues thereof, and nucleic acid molecules that encode the same are disclosed. A consensus CHIKV Env protein which includes CHIKV E1 consensus protein, CHIKV E2 consensus protein, CHIKV E3 consensus protein, or fragments and homologues thereof and nucleic acid molecules that encode the same are also disclosed. Compositions and recombinant vaccines comprising CHIKV consensus proteins, and methods of using them are disclosed. | 2011-05-05 |
| 20110104199 | MVA Expressing Modified HIV Envelope, GAG, and POL Genes - The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes. | 2011-05-05 |
| 20110104200 | Methods, compositions and kits for vegetative cell-based vaccines and spore-based vaccines - Methods for immunizing a subject to an antigen of an infectious agent, a tumor, or an allergen are provided, using vegetative cytoplasmic expression of the antigen or spore surface display of the antigen, and contacting the subject with a composition including a spore or a vegetative cell or both with or without an adjuvant. Also included are thermally-stable vaccine compositions using the method described above and kits including the compositions. | 2011-05-05 |
| 20110104201 | Porcine Reproductive and Respiratory Syndrome Vaccine Based on Isolate JA-142 - Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV. | 2011-05-05 |
| 20110104202 | Modified Influenza Virus For Monitoring And Improving Vaccine Efficiency - The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines. | 2011-05-05 |
| 20110104203 | VIRUS-LIKE PLATFORM FOR RAPID VACCINE DISCOVERY - The invention is directed to virus-like particles (VLPs) of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses. | 2011-05-05 |
| 20110104204 | SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN SCAFFOLDS - The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures. | 2011-05-05 |
| 20110104205 | HETEROLOGOUS PROTECTION AGAINST PASTEURELLA MULTOCIDA PROVIDED BY P. MULTOCIDA FUR CELLS AND THE OUTER-MEMBRANE PROTEIN EXTRACTS THEREOF - The invention relates to | 2011-05-05 |
| 20110104206 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS - The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically. | 2011-05-05 |
| 20110104207 | GYRASE INHIBITORS AND USES THEREOF - The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds. | 2011-05-05 |
| 20110104208 | Enzyme Treatment of Glucans - β-(1-6)-Glucanese treatment of glucan from yeast cells, pure or feed grade, especially yeast from the family | 2011-05-05 |
| 20110104209 | DNA SEQUENCE, AND RECOMBINANT PREPARATION OF THE GRASS POLLEN ALLERGEN LOL P4 - The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies. | 2011-05-05 |
| 20110104210 | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS - Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate. | 2011-05-05 |
| 20110104211 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2011-05-05 |
| 20110104212 | POLYMERIC COMPOSITIONS WITH ENHANCED SALINE HOLDING CAPACITY AND THEIR METHOD OF PREPARATION AND USE - Cross-linked polyelectrolyte polymers that absorb 60-fold or more, including greater than 60-fold, greater than 70-fold, greater than 80-fold, greater than 90-fold, greater than 100-fold, or greater than 110-fold or more, of their mass in a saline solution are disclosed. Methods for preparing such polymers with enhanced saline holding capacity and methods for treating diseases, disorders or conditions involving fluid overload and/or ion imbalances by administering the polymers are disclosed. | 2011-05-05 |
| 20110104213 | Porous Biomolecule-Containing Metal-Organic Frameworks - The present invention relates to compositions including porous biomolecule-containing metal-organic frameworks and methods for their preparation. The porous biomolecule-containing metal-organic frameworks can include a metal component and a biomolecule component. The pores located within the frameworks have a pore space and said pore space is capable to adsorb materials therein. These compositions of the present invention are useful in a wide variety of applications, such as, but not limited to, hydrogen and carbon dioxide sequestration, separation and storage; carbon dioxide uptake; and drug storage and release. | 2011-05-05 |
| 20110104214 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 2011-05-05 |
| 20110104215 | TRANSDERMALLY ABSORBABLE PREPARATION - Disclosed is a novel transdermally absorbable preparation which enables the efficient, stable and long-term administration of a drug to a living body. More specifically, the transdermally absorbable preparation comprises: a laminate comprising an outer film, a drug-containing layer and a support layer laminated in this order from the side to be contacted with the skin; and a fixing means for fixing the laminate on the skin. In the transdermally absorbable preparation, the outer film is a drug-permeable polymer film that can control the release of the drug into the skin and is provided as a surface of the laminate which is to be contact with the skin. | 2011-05-05 |
| 20110104216 | PROCESSES FOR THE PREPARATION OF A BATCH OF AN ACTIVE PHARMACEUTICAL INGREDIENT, A CONTAINER COMPRISING CRYOGRANULES OF AN ALLERGEN PRODUCT, AND A CRYOGRANULE OF AN ALLERGEN PRODUCT - The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying. | 2011-05-05 |
| 20110104217 | Bioactive Peptides and Method of Using Same - Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation. | 2011-05-05 |
| 20110104218 | METHODS AND COMPOSITIONS FOR PRODUCING HYDROGEL CAPSULES COATED FOR LOW PERMEABILITY AND PHYSICAL INTEGRITY - Methods and compositions for producing hydrogel capsules enveloped with at least one coating layer is disclosed. The coating formulations deposited on the surface of the capsules can improve the physical integrity and the water-retention properties of the alginate beads. The coating formulations can be sequentially applied in various combinations to obtain desirable properties, such as improved physical integrity, mechanical strength, and low permeability, that can extend the shelf-life of the capsules when incorporated into various consumer products. | 2011-05-05 |
| 20110104219 | DENTURE CARE COMPOSITION - A denture care composition comprising one or more denture care actives and one or more water insoluble carriers, wherein the composition is bioerodible, not a denture adhesive, and substantially free of polybutene with a molecular weight of about 300 to about 3000 when the composition is not an article, and is applied to dentures. | 2011-05-05 |
| 20110104220 | PIGMENTS - The present invention relates to inorganic spherical pigments which are based on spherical particles having a particle diameter of 0.1-100 μm and are coated on the surface with agglomerates selected from the group ZrO | 2011-05-05 |
| 20110104221 | Deposition Of Lipophilic Active Material In Surfactant Containing Compositions - The present invention relates to a controlled release carrier system that can be incorporated into rinse-off application products containing at least one surfactant such as heavy duty liquids (HDL), Rinse Cycle Fabric Softeners (RCFS), Shampoos, Hair Conditioners, Shower Gels, cleansing products, and that enhance deposition of lipophilic active materials like fragrance, fine perfumes, flavours and other volatile compounds onto a surface. The fragrance composition is encapsulated within a shell comprising a silicon-containing material and the shell has a mean diameter size which is lower than 30 micrometer. The surfactant composition containing the fragrance composition is washed off and the fragrance is progressively released. | 2011-05-05 |
| 20110104222 | COSMETIC - A cosmetic composition contains the following components (A), (B) and (C):
| 2011-05-05 |
| 20110104223 | MICROEMULSION SPORICIDAL COMPOSITION - A sporicidal composition comprising an aromatic dialdehyde; a medium chain linear alcohol; a surfactant; greater than 0.2% by weight based on the total weight of the composition of a base; and water, wherein the sporicidal composition is a microemulsion having a pH ranging from about 11 to about 13. | 2011-05-05 |
| 20110104224 | Textile Finishing For Insect Repellency - The invention is drawn to a method of producing a textile flat structure with insect-repellent properties by applying a solution comprising an insect repellent and a binder to a textile flat structure, wherein the binder is a combination of a silicone elastomer of formula (I) and a silicone crosslinker of formula (II), provided that the insect repellent is not microencapsulated, and that the solution is free from acrylate binders. The treated textile flat structures are characterized by excellent washing permanence. | 2011-05-05 |
| 20110104225 | POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR - A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide; or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue. | 2011-05-05 |
| 20110104226 | PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN A1 LOOP 2 OR BETA2 LOOP 1 OF AN ADRENORECEPTOR - A peptide having an ED | 2011-05-05 |
| 20110104227 | ABSORBABLE POLYETHYLENE DIGLYCOLATE COPOLYMERS TO REDUCE MICROBIAL ADHESION TO MEDICAL DEVICES AND IMPLANTS - The present invention is directed to absorbable polyether esters that have been found to reduce bacterial adhesion to materials such as medical devices and implants. More specifically, the invention is directed to novel amorphous co-polymers comprising polyethylene diglycolate (PEDG) copolymerized with lactide-rich monomers. | 2011-05-05 |
| 20110104228 | SELF-ELIMINATING COATINGS - The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to enhance biocompatibility and to control the local delivery of biologically active agents. | 2011-05-05 |
| 20110104229 | Bone Xenograft - The invention provides an article of manufacture comprising a substantially non-immunogenic bone xenograft (X) for the implantation into a defect (D) located in a bone portion ( | 2011-05-05 |
| 20110104230 | COMPOSITIONS OF NOVEL BONE PATCH IN BONE AND VASCULAR REGENERATION - A bone patch and method for treating a bone condition of an animal. The bone patch includes a composition of ingredients. The composition of ingredients include: stem cells; signaling molecules for osteoblast/endothelial differentiation; and scaffold material. The method for treating a bone condition includes: applying the bone patch to the animal for bone regeneration, treatment of a fractured bone, and/or treatment of a bone disorder. | 2011-05-05 |
| 20110104231 | BIOCERAMIC AND BIOPOLYMER COMPOSITE - The invention provides a high performance porous bioceramic composite that has a high compression strength resulting from the ability to compression form a bioceramic precursor material and a pore forming agent under a high pressure load prior to sintering and/or removing the pore forming agent. Methods of making and using the same are also provided. Optionally, a biopolymer and/or therapeutic agent may be infused into the pores thereby forming the bioceramic composite. | 2011-05-05 |
| 20110104232 | Sustained Release Systems of Ascorbic Acid Phosphate - A novel method of preparing a controlled release composition is disclosed. Specifically, the present invention relates to a method of preparing controlled release compositions of ascorbic acid phosphate and absorbable polymers. Also disclosed is a novel controlled release composition of ascorbic acid phosphate made by the method of the present invention. | 2011-05-05 |
| 20110104233 | FLOWABLE COMPOSITION THAT SETS TO A SUBSTANTIALLY NON-FLOWABLE STATE - Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent, (ii) a polymer and (iii) an effective amount of the therapeutic agent, the flowable composition being capable of setting to form a substantially non-flowable composition at a physiological temperature or as the solvent contacts bodily fluid at or near the target tissue site, wherein the substantially non-flowable composition is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal. | 2011-05-05 |
| 20110104234 | Biodegradable Modified Carpolactone Polymers for Fabrication and Coating Medical Devices - Disclosed herein are biodegradable modified caprolactone polymers for coating and forming medical devices. The properties of the polymers are fine tuned for optimal performance depending on the medical purpose. Moreover, the polymers are suitable for the controlled in situ release of drugs at the treatment site. | 2011-05-05 |
| 20110104235 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS OF THE NAIL UNIT - The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals. | 2011-05-05 |
| 20110104236 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF OCULAR INFLAMMATORY DISORDERS - The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye. | 2011-05-05 |
| 20110104237 | BONE STRENGTHENING FOOD SUPPLEMENT - Black beans B are coated with a mineral layer | 2011-05-05 |
| 20110104238 | WETTABLE FILLERS FOR IMPROVED RELEASE OF HYDROPHILIC MATERIALS FROM CHEWING GUM COMPOSITIONS - A chewing gum is provided in the present disclosure. In an embodiment, the chewing gum comprises at least one wettable filler wherein the wettable filler aids in producing an increasing release of one or more hydrophilic additives. In another embodiment, the chewing gum comprises a wettable filler having a γ | 2011-05-05 |
| 20110104239 | PROBIOTIC CHEWING GUM METHOD OF MANUFACTURE - An extruded, centerfilled or coated confectionary material is provided which contains a probiotic which is capable of having a shelf life greater than about six months. A chewing gum production method is also provided which produces stick, centerfilled and coated chewing gum with probiotics without substantial loss of probiotics due to excess water, heat or pressure. Probiotics may be included in the chewing gum mass of the stick or coated chewing gum, in the liquid or powder center of a centerfilled gum, in the coating of the coated chewing gum, or as an additional layer upon the stick. The probiotics delivered to the oral cavity provide an oral health benefit to the consumer through suppression of pathogenic bacteria. | 2011-05-05 |
| 20110104240 | Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections - The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides methods and uses for treating wounds, microbial infections and dermatological disorders and for preserving meat products. | 2011-05-05 |
| 20110104241 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME - Provided are a percutaneous absorption enhancer excellent in an enhancing effect on percutaneous absorption of a wide range of drugs and excellent in compatibility with an adhesive base, and a transdermal preparation using the percutaneous absorption enhancer. The percutaneous absorption enhancer includes a sulfosuccinate or a salt thereof and an alkyl glycoside or an alkyl thioglycoside. | 2011-05-05 |
| 20110104242 | CARTILAGE MATERIAL - Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect. | 2011-05-05 |
| 20110104243 | First aid formulations of turmeric powder lavender essential oil and glycerin for dressing wounds - A formulation made from natural substances, for healing cuts, bruises, wounds, and the like on the skin, has a natural-heal compound that has proportion of very fine | 2011-05-05 |
| 20110104244 | TRANSDERMAL THERAPEUTIC SYSTEM PROVIDED WITH IMPROVED LONG-TERM CARRYING COMFORT - The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterized in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time. | 2011-05-05 |
| 20110104245 | PRESSURE-SENSITIVE ADHESIVES BASED ON ETHYLENE-VINYL ACETATE COPOLYMERS AND ADHESIVE RESINS, FOR MEDICAL APPLICATION PURPOSES - A pressure sensitive adhesive for medicinal application purposes, based on ethylene-vinyl acetate copolymers is characterized in that it contains as polymer component (A) an ethylene-vinyl acetate copolymer or a combination of at least two ethylene-vinyl acetate copolymers, and as component (B) an adhesive resin or a combination of adhesive resins at a portion of up to 55%-wt, relative to the sum of components (A) and (B) without active substances or other auxiliary substances. | 2011-05-05 |
| 20110104246 | METHOD OF WOUND TREATMENT USING LIQUID GALLIUM NITRATE - A pharmaceutical composition and method for topical wound treatment by topical treatment with gallium salts, preferably gallium nitrate. In a preferred embodiment, the gallium nitrate is in an aqueous form without coagulation inhibitors such as citrate. The aqueous gallium salt formulation may be administered by a variety of methods including spraying, topical lotions, topical foams, and/or bandages containing or packaged with breakable ampoules of aqueous gallium salt formulations, and liquid bandage formulations. The aqueous gallium salt formulation may additionally contain other active and inactive ingredients, such as viscosity modifying agents, foaming agents, antiseptics, antibiotics, enzymes, fibrinogen, fibrin, polymers and growth factors. | 2011-05-05 |
| 20110104247 | COMPOSITION FOR STABILIZING BETA-BLOCKER AND TRANSDERMALLY ABSORBABLE PREPARATION COMPRISING THE SAME - The present invention relates to a transdermally absorbable composition which is capable of retaining a β-blocker stably for a long period. More specifically, the present invention relates to a transdermally absorbable composition for stabilizing a β-blocker, which comprises a polymer compound having an amino group, a polyvalent carboxylic acid ester, a fatty acid ester and an acrylic polymer compound. | 2011-05-05 |
| 20110104248 | LIPOSOMES AND IMMUNOPOTENTIATING COMPOSITIONS CONTAINING THE SAME - It is an object to enhance immunopotentiating activity of a glycosphingolipid. | 2011-05-05 |
| 20110104249 | Oncotherapeutic Application of Inhibitors of High-Affinity Glucose Transporters - The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods. | 2011-05-05 |
| 20110104250 | Redox-gated Liposomes - The present invention provides lipid compounds for delivering therapeutic amounts of active agents in response to enzymatic activities of cancer tissues. Lipid compositions may include one or more drugs, or a biologically-active agent, encapsulated within liposomes. | 2011-05-05 |
| 20110104251 | Cosmetic Composition And Method For Retarding Hair Growth - The present invention comprises cosmetic compositions and methods for retarding hair growth comprising a combination of an ornithine decarboxylase inhibitor, an anti-angiogenic active and an anti-inflammatory. | 2011-05-05 |
| 20110104252 | ANTI-APOPTOTIC GENE SCC-S2 AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells. | 2011-05-05 |
| 20110104253 | AGENT FOR INTRA-ARTICULAR INJECTION - The present invention relates to agents for intra-articular injection that contain a mixture of alpha-tocopherol, phospholipids, proteoglycans, and a cortisone crystal suspension or a cortisone crystal solution. The agents are suitable for therapy of rheumatic diseases, in particular of arthrosis. | 2011-05-05 |
| 20110104254 | Medicament for treatment of tumors wherein hedgehog/smoothened signaling is employed for inhibition of apoptosis of the tumor cells - This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC's and other tumors that use the hedgehog/smoothened signal transduction pathway for proliferation and prevention of apoptosis. | 2011-05-05 |
| 20110104255 | THERAPEUTIC AGENT FOR FIBROID LUNG - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent. | 2011-05-05 |
| 20110104256 | METHODS FOR TREATING OR PREVENTING COLORECTAL CANCER - The present invention provides, for example, methods for treating or preventing colorectal cancer with an anti-IGF1R antibody in association with sunitinib or a combination of leucovorin and 5-fluorouracil. | 2011-05-05 |
| 20110104257 | POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPOUND-INDUCED OTOTOXICITY - Methods of determining a subjects ototoxicity risk from administration of platinum-coordinating compounds having an ototoxicity risk, methods of administering a platinum-coordinating compound having an ototoxicity risk and oligonucleotides, peptide nucleic acids, arrays and addressable collections for performing embodiments of the methods are provided herein. | 2011-05-05 |
| 20110104258 | TECHNIQUE FOR DRUG AND GENE DELIVERY TO THE CELL CYTOSOL - Provided herein is a composition, a method, and a system for delivering a functional molecule to the cytosol of a cell, comprising a liposome configured to be taken into a cell, including by a process selected from the group consisting of endocytosis, pinocytosis or phagocytosis, the liposome comprising a phase transforming liquid with vapor pressure capable of forming a gas at low pressure, said liquid being associated with the liposome, and the liposome further comprising at least one functional molecule selected from the group consisting of a therapeutic molecule, a detectable label, and a targeting molecule. | 2011-05-05 |
| 20110104259 | PROCESSES FOR TASTE-MASKING OF INHALED FORMULATIONS - The present invention provides novel processes and methodologies to minimize the bitter or otherwise unpleasant taste, to minimize the tendency to stimulate the cough reflex, or to minimize oropharyngeal deposition of medically-active compounds administered by the pulmonary/inhalation route and to deliver hydroxychloroquine (HCQ) either singularly or in combination with an antimalarial and aminoquinolone by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the bitter or otherwise unpleasant taste of HCQ or any potential to stimulate the cough reflex, and to deliver a dopaminergic compound or its prodrug, including ABT-431 by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate the cough reflex, and to deliver a lantibiotic, including duramycin by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate throat irritation. | 2011-05-05 |
| 20110104260 | VACCINE AGAINST VARICELLA ZOSTER VIRUS - Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed | 2011-05-05 |
| 20110104261 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS - The present invention provides for the development of endocytosis-sensitive probes, and a remote method for measuring cellular endocytosis. These probes are based on the reduced water permeability of a nanoparticle or liposomal delivery system, and inherent degradability or disruption of barrier integrity upon endocytosis. The invention also provides for liposomes having combined therapeutic and diagnostic utilities by co-encapsulating ionically coupled diagnostic and therapeutic agents, in one embodiment, by a method using anionic chelators to prepare electrochemical gradients for loading of amphipathic therapeutic bases into liposomes already encapsulating an imaging agent. The invention provides for imaging of therapeutic liposomes by inserting a lipopolymer anchored, remotely sensing reporter molecules into liposomal lipid layer. The invention allows for an integrated delivery system capable of imaging molecular fingerprints in diseased tissues, treatment, and treatment monitoring. | 2011-05-05 |
| 20110104262 | Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent - There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof. | 2011-05-05 |
| 20110104263 | CLAUDIN-4 BINDING PEPTIDES, COMPOSITIONS AND METHODS OF USE - The disclosure provides methods and compositions useful for treating claudin-4 associated disorders including cell proliferative disorders. The disclosure also provide claudin-family binding peptides useful in the methods of the disclosure. | 2011-05-05 |
| 20110104264 | Gastric acid secretion inhibiting composition - A method for the treatment of at least one symptom of gastro-esophageal reflux disease (GERD) in a human suffering from GERD administers an oral pharmaceutical dosage form into a gastro-intestinal tract of a human suffering from GERD. The oral pharmaceutical dosage form contains an acid susceptible proton pump inhibitor or salt thereof (PPI), an H2 receptor antagonist or salt thereof (H2RA), a pharmaceutically acceptable carrier, and optionally an antacid agent and/or alginate. The PPI is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole, pariprazole, leminoprazole, their pharmaceutically acceptable salts, enantiomers and salts of enantiomers and is in a form that protects the PPI from degradation in a stomach. The H2RA is selected from cimetidine, ranitidine, nizatidine and famotidine, their pharmaceutically acceptable salts, isomers and salts of isomers. The PPI is administered in combination with the H2RA for passage into a small | 2011-05-05 |
| 20110104265 | COMPOSITIONS AND METHODS OF TARGETED NANOFORMULATIONS IN THE MANAGEMENT OF OSTEOPOROSIS - A composition and method for treating a bone condition of an animal. The compostion includes nanoparticles; a targeted moiety covalently bonded to an outer surface of each nanoparticle; and osteoblast stimulating molecules encapsulated within each nanoparticle. The method for treating a bone condition includes introducing the composition into the animal. | 2011-05-05 |
| 20110104266 | MULTIMICROPARTICULATE PHARMACEUTICAL FORMS FOR ORAL ADMINISTRATION - The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. | 2011-05-05 |
| 20110104267 | Pharmaceutical compositions of antiretrovirals - The present invention relates to the stable pharmaceutical dosage forms of combination of antiretroviral agents. More particularly, the present invention relates to stable pharmaceutical dosage forms of Lamivudine, Zidovudine and Nevirapine, prepared by granulation technology. | 2011-05-05 |
| 20110104268 | GALENIC APPLICATIONS OF SELF-EMULSIFYING MIXTURES OF LIPIDIC EXCIPIENTS - A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps. | 2011-05-05 |
| 20110104269 | COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS - An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestine following oral administration. A drug delivery composition for delivering a corticosteroid drug to the intestine also includes: (a) a sustained release component comprising a corticosteroid drug, an alkali-containing ethylcellulose material and an acid; and (b) a delayed release component which substantially prevents release of the sustained release component until the composition reaches the intestine following oral administration. The compositions of the invention are useful for treating inflammatory diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, and for treating glomerulonephritis. | 2011-05-05 |
| 20110104270 | PROCESS FOR PRODUCTION OF SPHERICAL MICROPARTICLES COMPRISING TAMSULOSIN HYDROCHLORIDE - The present invention provides a method for producing spherical fine particles containing tamsulosin hydrochloride, the method includes the steps of: ( | 2011-05-05 |
| 20110104271 | Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients - Compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. The recompactibility performance of such compositions is improved through the use of calcium phosphate having a relatively small particle size, e.g., a median particle size of not more than about 20 microns or not more than about 10 microns. | 2011-05-05 |
| 20110104272 | GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF ACETAMINOPHEN AND PHENYLEPHRINE - Compositions and methods for the treatment of a mammal suffering from pain and from nasal congestion or ophthalmic disorders are described. More specifically, a dosage form designed for release of acetaminophen and phenylephrine is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time. | 2011-05-05 |
| 20110104273 | GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE - Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described. | 2011-05-05 |
| 20110104274 | NOVEL COMPOSITION AND USES THEREOF, IN PARTICULAR COSMETIC USES, FOR TREATING SKIN DEHYDRATION - The present invention relates to the use of a combination comprising gamma-linolenic acid and at least one green tea polyphenol, in which the ratio of the gamma-linolenic acid to the green tea polyphenol ranges from approximately 1 to approximately 10, for increasing the in vitro and ex vivo differentiation of keratinocytes. | 2011-05-05 |
| 20110104275 | METHODS AND KITS FOR TREATING CLUSTER HEADACHE DISORDERS - The invention features methods and kits employing bromolysergide in therapies for the treatment of cluster headache disorders. | 2011-05-05 |
| 20110104276 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 2011-05-05 |
